Pharmacodynamics of High-Dose Chemotherapy

Author(s): Yago Netio

Journal Name: Current Drug Metabolism

Volume 2 , Issue 1 , 2001

Become EABM
Become Reviewer

Abstract:

There is usually considerable variability in anticancer drug plasma levels when delivered at high doses requiring stem-cell support. Given their narrow therapeutic windows and wide interpatient pharmacokinetic variability, drug monitoring and pharmacokinetic-directed dosing represent an attractive strategy in this setting. A major previous requirement to successful application of therapeutic drug monitoring is identification of a significant and clinically meaningful pharmacodynamic correlation between a pharmacokinetic parameter and a toxic or therapeutic outcome, or preferably, both. In this review, we will analyze the current knowledge of identified pharmacodynamic correlations in high-dose chemotherapy. We will summarize the observations from other authors and our own, on drugs employed at high doses, such as cyclophosphamide, melphalan, busulfan, carmustine, paclitaxel, or docetaxel.

Keywords: Pharmacodynamics High-Dose Chemotherapy, anticancer drug plasma levels, cyclophosphamide, melphalan, busulfan, carmustine, paclitaxel, docetaxel

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 1
Year: 2001
Page: [53 - 66]
Pages: 14
DOI: 10.2174/1389200013338720

Article Metrics

PDF: 16